Targeting the RNA regulator HuR in acute traumatic brain injury mitigates secondary injury and improves functional outcome by suppressing neuroinflammation
This study demonstrates that the small molecule HuR inhibitor SRI-42127 mitigates secondary injury and improves functional outcomes in a mouse model of traumatic brain injury by suppressing neuroinflammation through the inhibition of HuR nucleocytoplasmic translocation in glial cells.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
When the brain suffers a sudden, violent blow, the damage does not stop when the impact ends. In the minutes and hours that follow, the brain's own defense systems can turn against it. Specialized cells that usually act as the brain's immune sentinels begin to release a flood of chemical signals intended to fight infection or repair damage. However, in the context of a traumatic injury, this response becomes a runaway fire. These signals attract other immune cells from the bloodstream, cause swelling that squeezes delicate tissue, and break down the tight barriers that normally keep the brain safe. This secondary wave of injury often causes more long-term harm than the initial physical trauma, leading to lasting problems with movement, memory, and thinking. Scientists have long searched for a way to stop this internal cascade without shutting down the body's necessary healing processes, but the sheer number of different chemicals involved has made finding a single target extremely difficult.
Researchers at the University of Alabama at Birmingham have now identified a specific molecular switch that controls this dangerous flood of inflammatory signals and demonstrated that turning it off can significantly reduce brain damage. The study focuses on a protein called HuR, which acts as a manager for the instructions that cells use to build inflammatory chemicals. Under normal conditions, HuR stays inside the nucleus of a cell, but when the brain is injured, it moves out into the main body of the cell, where it helps produce massive amounts of harmful substances. The team tested a small molecule drug called SRI-42127, designed to lock HuR inside the nucleus so it cannot do its job. In mice that suffered a controlled brain injury, giving this drug via intraperitoneal injection starting just one hour after the trauma and continuing with doses every six hours for five days stopped the inflammatory cascade, reduced swelling and tissue death, and allowed the animals to recover their balance and memory much better than untreated mice.
The researchers used a precise method to simulate a human brain injury in mice, striking a specific area of the skull to damage the cortex and hippocampus, regions critical for movement and spatial memory. They then administered the drug SRI-42127 through an intraperitoneal injection, starting just one hour after the injury and continuing with doses every six hours for five days. To see if the treatment worked, they watched how the mice performed on simple tasks. Untreated mice struggled to cross a narrow beam without slipping their feet and had trouble remembering where objects were placed in a room, indicating damage to their motor control and spatial memory. In contrast, the treated mice moved with much greater stability and quickly recognized when an object had been moved to a new spot, performing nearly as well as healthy, uninjured animals.
Looking inside the brains of these mice, the team found that the drug had successfully stopped the molecular machinery responsible for the damage. In untreated mice, the HuR protein had moved out of the nucleus and into the cell's main compartment, where it helped drive the production of inflammatory chemicals. In the treated mice, HuR remained trapped in the nucleus, unable to trigger the production of these harmful signals. As a result, the brain showed far less swelling, and the blood-brain barrier, which usually leaks and lets dangerous substances in after an injury, remained much more intact. The treated brains also had significantly fewer signs of cell death and contained far fewer invading immune cells that typically rush in to cause further tissue destruction.
The study revealed that this single intervention had a broad effect because it stopped the production of many different inflammatory chemicals at once. Instead of trying to block one specific chemical, which often fails because the body uses many different pathways to cause damage, the drug stopped the master regulator that controls the production of dozens of them. This included chemicals that attract immune cells to the injury site and enzymes that break down the structural support of blood vessels. By preventing the initial surge of these signals, the drug effectively dampened the entire inflammatory response. The researchers observed that this protection lasted even after the drug was no longer in the system, with the treated mice showing smaller areas of dead tissue and less scarring a week after the injury.
While the results in the mice were clear, the researchers noted that the human brain is more complex and that the timing of treatment is critical. The drug worked best when given very soon after the injury, suggesting that the window to stop this secondary damage is narrow. The study also highlighted that while stopping inflammation is beneficial in the acute phase, the body eventually needs some of these signals to begin the long-term repair process, so the treatment strategy would need to be carefully managed to avoid interfering with healing later on. Nevertheless, this work provides strong evidence that targeting the RNA regulator HuR offers a promising new path for treating traumatic brain injury, potentially turning off the internal fire that often does the most lasting damage.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.